Han, S., Yang, F., Zhang, Y., Ye, X., Shi, H., Jia, B., Bi, X., Wahafu, W., Bai, H., Hu, L., Wang, X., Xing, N. (2025). Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4588